BioMérieux said that its VIDAS 3 immunoassay platform has received an EU CE mark, making it commercially available in Europe and other countries recognizing the CE marking.

In a statement, François Lacoste, corporate vice president of BioMérieux's immunoassay unit, said the company now plans to pursue regulatory approval for the platform in other countries – the US and China, in particular.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.